Intramyocardial injection of bone marrow mononuclear cells in chronic myocardial ischemia patients after previous placebo injection improves myocardial perfusion and anginal symptoms: An intra-patient comparison

• DOI: 10.1016/j.ahj.2012.08.008
• Publication Date: 2012-10-16T15:31:03Z
• Authors: Sander F. Rodrigo; Jan van Ramshorst; Saskia L. Beeres; Imad Al Younis; Petra Dibbets-Sch...; Albert de Roos; Willem E. Fibbe; Jaap J. Zwaginga; Martin J. Schalij; Jeroen J. Bax; Douwe E. Atsma
• Keywords: Male; Myocardial Ischemia; Bone Marrow Cells; Severity of Illness Index; Angina Pectoris; Injections; 03 medical and health sciences; 0302 clinical medicine; Coronary Circulation; Humans; Aged; Tomography, Emission-Computed, Single-Photon; Cross-Over Studies; Myocardium; Middle Aged; Magnetic Resonance Imaging; 3. Good health; Research Design; Chronic Disease; Heart Function Tests; Leukocytes, Mononuclear; Quality of Life; Female; Cardiology and Cardiovascular Medicine

We recently demonstrated in a randomized, double-blind, placebo-controlled trial that intramyocardial bone marrow cell (BMC) injection is associated with improvements in myocardial perfusion and anginal symptoms in chronic myocardial ischemia patients. In the present study the results of the crossover phase of this trial, in which patients previously treated with placebo received autologous BMC injections are reported. This allows a unique intra-patient comparison on the effect of BMC versus placebo injection with elimination of patient-related confounding factors.In 16 patients (14 male, 64 ± 10 years), who previously received intramyocardial placebo injections in the setting of a randomized trial, 100 × 10(6) BMC were injected using the NOGA-system. Canadian Cardiovascular Society angina score and quality of life were evaluated at baseline, 3 and 6 months. Tc-99m single photon emission computed tomography and magnetic resonance imaging were performed at baseline and 3 months to assess myocardial perfusion and left ventricular (LV) function.Canadian Cardiovascular Society score and quality of life improved significantly after BMC injection as compared to placebo (P = 0.01 and P = 0.02, respectively). Single photon emission computed tomography revealed a significant greater improvement (P = 0.03) in summed stress score after BMC injection as compared to placebo. LV end-systolic volume significantly decreased after BMC injection but not after placebo injection. LV end-diastolic volume and LV ejection fraction did not change.Intramyocardial BMC injection in patients with chronic myocardial ischemia who previously received intramyocardial placebo treatment resulted in significant improvement in angina symptoms and myocardial perfusion. These results confirm the outcome of our previously reported randomized trial.